The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease

Ferrer, Cristina Suárez; Barnó, Marta Abadía; Arranz, Eduardo; Jochems, Andrea; Ramírez, Laura García; Cordón, Joaquín Poza; Herranz, Marta Jaquotot; Arencibia, Alberto Cerpa; Arranz, María Dolores Martín

doi:10.17235/reed.2019.5797/2018

Cited by 10 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This important finding relates to studies of CLP in IBD and RA, where CLP is routinely used as a disease activity marker ( 14 , 43 ). CLP is a sensitive marker of inflammation mainly reflecting different degrees of disease activity and thus may guide treatment decisions, as proposed in other conditions like IBD ( 13 ) and RA ( 15 , 44 ). In addition, CLP has the potential to serve as a possible diagnostic biomarker to differentiate inflammatory neuropathies from non-inflammatory neuropathies, as only a small percentage of CIDP patients present with nodal, paranodal, and aGAAbs.…”

Section: Discussionmentioning

confidence: 99%

“…Calprotectin (CLP), a calcium-binding protein of the S100 family, performs various biological functions via interaction with Toll-like receptor 4 ( 11 ) and is mainly released by activated leucocytes triggering signaling pathways involved in inflammatory processes ( 12 ). Thus, CLP has been investigated in other autoimmune diseases, mainly inflammatory bowel disease (IBD) ( 13 , 14 ) and rheumatoid arthritis (RA) ( 15 ), where CLP strongly predicted disease activity and treatment response. CLP leads to the release of pro-inflammatory cytokines ( 16 , 17 ) and induction of auto-reactive CD8+ T cells ( 17 ), which play a key role in the pathogenesis of CIDP ( 18 , 19 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity

et al. 2021

View full text Add to dashboard Cite

Background: In chronic inflammatory demyelinating polyneuropathy (CIDP), there is an urgent need for biomarkers to monitor ongoing disease activity. Serum calprotectin (CLP) induces signaling pathways involved in inflammatory processes and has been shown to correlate with markers of disease activity in other autoimmune disorders. Thus, we wanted to study the potential value of CLP in comparison to serum neurofilament light chain (sNfl) to monitor disease activity.Materials and Methods: Sera from 63 typical and atypical CIDP and 6 MMN patients with varying degrees of disease activity were analyzed in comparison with 40 healthy controls (HC) in a cross-sectional design. Association of CLP and sNfl levels with socio-demographics, disease duration, CIDP disease activity scale (CDAS), and impairment status [medical research council-sum score (MRC-SS), the inflammatory neuropathy cause and treatment disability score (INCAT-DS), grip strength, and maximum walking distance], patient-reported outcome (PRO) parameters [SF-36 questionnaire, Beck's depression index (BDI), and fatigue severity scale (FSS)], as well as treatment regime were investigated using uni- and multivariate analysis.Results: CLP and sNfl levels were significantly higher in all CIDP patients compared to HC (p = 0.0009). Multivariate analysis adjusted for age and gender revealed that CLP acts as an independent predictor for CIDP and MMN. CLP was significantly associated with active disease course according to CDAS and correlated with MRC-SS, whereas sNfl correlated with parameters of disease impairment. There was no correlation with PRO, except for sNfl and the mental health composite score. Subgroup analysis revealed no differences between typical CIDP and atypical variants.Conclusions: CLP was elevated in CIDP and variants and was associated with active disease course, whereas sNfl shows further potential as biomarker of axonal degeneration. Thus, CLP might be a suitable additive biomarker for measurement of ongoing inflammation, which is greatly needed to guide better patient care in CIDP.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Fecal calprotectin predicts mucosal active disease with a >90% positive predictive value in patients with CD (159). Recently, Suarez et al found that serum calprotectin had higher AUC for disease activity than CRP, erythrocyte sedimentation rate, hemoglobin, and platelets (160). Oxidative stress plays an important role in IBD pathogenesis.…”

Section: Miscellaneous Indicatorsmentioning

confidence: 99%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic, inflammatory disorder of the gastrointestinal tract. As the novel therapeutic goal and biologicals are widely recognized, accurate assessment of disease and prediction of therapeutic response have become a crucial challenge in clinical practice. Also, because of the continuously rising incidence, convenient and economical methods of diagnosis and clinical assessment are urgently needed. Recently, serum biomarkers have made a great progress and become a focus in IBD study because they are non-invasive, convenient, and relatively inexpensive than are markers in biopsy tissue, stool, breath, and other body fluids. Aims: To review the available data on serological biomarkers for IBD. Methods: We searched PubMed using predefined key words on relevant literatures of serum biomarkers regarding diagnosis, evaluation of therapeutic efficacy, surveillance of disease activity, and assessment of prognosis for IBD. Results: We reviewed serological biomarkers that are well-established and widely used (e.g., C-reactive protein), newly discovered biomarkers (e.g., cytokines, antibodies, and non-coding RNAs), and also recently advancements in serological biomarkers (e.g., metabolomics and proteomics) that are used in different aspects of IBD management. Conclusions: With such a wealth of researches, to date, there are still no ideal serum biomarkers for IBD. Serum profiling and non-coding RNAs are just starting to blossom but reveal great promise for future clinical practice. Combining different biomarkers can be valuable in improving performance of disease evaluation.

show abstract

“…A meta-analysis evaluated 13 studies, including 744 patients with UC and 727 with CD and found that FC had a higher area under the curve for UC than CD, 0.93 (95% confident interval [CI] 0.89–0.97) and 0.88 (95% CI 0.83–0.93), respectively [35]. However, while serum calprotectin levels in patients with IBD, in particular CD, correlate with CRP, this does not extend to a correlation with FC levels and/or active endoscopic disease [36-38]. This suggests that serum (and consequently urinary) levels of calprotectin may be more useful as biomarkers of systemic inflammation than specifically of GIT inflammation.…”

Section: Discussionmentioning

confidence: 99%

A Pilot Study Evaluating Novel Urinary Biomarkers for Crohn’s Disease

Wall

Gearry

et al. 2020

Inflamm Intest Dis

View full text Add to dashboard Cite

Introduction: Although collecting faeces and blood samples are considered non-invasive methods of monitoring Crohn’s disease (CD), these methods are less preferred by some patients. This study utilized urine as an alternative to evaluate four disease biomarkers in young adults with active CD before and after exclusive enteral nutrition (EEN) therapy. Methods: Urine samples collected at baseline (W0) and after 8 weeks (W8) of EEN therapy were assayed by ELISA for levels of intestinal fatty acid-binding protein (I-FABP), liver fatty acid-binding protein (L-FABP), claudin-3, and calprotectin. Levels of each biomarker were also compared with standard clinical parameters, including disease indexes, nutrient, and inflammatory markers. Results: Of the paired urine samples from 14 patients, 10 were female and 12 were newly diagnosed with CD. Urinary I-FABP:Cr (standardized to urine Cr) levels were significantly reduced, while urinary L-FABP:Cr levels increased following EEN therapy. Urinary L-FABP:Cr correlated positively with serum insulin-like growth factor 1 (IGF-1) (r = 0.60, p = 0.02). Urinary CLND3:Cr and calprotectin:Cr levels were not significantly different after treatment. Conclusion: I-FABP is a potential urinary biomarker of disease activity in adults with CD, while urinary L-FABP may be an indirect marker of nutritional status in adults with CD. CLND3 and calprotectin do not appear to have roles as urinary biomarkers in CD. These findings warrant further investigations using a larger sample size.

show abstract

The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease

Cited by 10 publications

References 19 publications

Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity

Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity

Serum Biomarkers for Inflammatory Bowel Disease

A Pilot Study Evaluating Novel Urinary Biomarkers for Crohn’s Disease

Contact Info

Product

Resources

About